{"id":"placebo-vehicle-cream","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo or vehicle cream is an inert topical formulation used as a comparator in clinical trials to establish the efficacy of an active drug. It typically contains the same base ingredients (emollients, preservatives, etc.) as the active formulation but lacks the therapeutic agent, allowing researchers to distinguish true drug effects from vehicle effects or natural disease progression.","oneSentence":"Placebo/vehicle cream contains no active pharmaceutical ingredient and serves as a control formulation in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:44.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03372811","phase":"PHASE2","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)","status":"COMPLETED","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2015-06-11","conditions":"Psoriasis Vulgaris, Topical Administration","enrollment":88},{"nctId":"NCT07482787","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","status":"NOT_YET_RECRUITING","sponsor":"Paradigm Therapeutics","startDate":"2026-05-15","conditions":"Epidermolysis Bullosa (EB)","enrollment":80},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT06286397","phase":"PHASE2","title":"Topical Anti-Androgens in Pilonidal Sinus Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-01-10","conditions":"Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus","enrollment":75},{"nctId":"NCT07079969","phase":"PHASE2","title":"Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04","conditions":"Knee Pain Chronic","enrollment":32},{"nctId":"NCT07426120","phase":"PHASE3","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","status":"RECRUITING","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2026-02-01","conditions":"Psoriasis Vulgaris, Topical Administration, Phase III","enrollment":300},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT07345390","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","startDate":"2026-01-10","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT07301515","phase":"NA","title":"Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin","status":"COMPLETED","sponsor":"Klira Skin","startDate":"2025-03-01","conditions":"Photoaging, Photodamage, Mitochondrial Damage","enrollment":52},{"nctId":"NCT06832618","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-17","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT05190770","phase":"PHASE2","title":"A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-15","conditions":"Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I","enrollment":18},{"nctId":"NCT07203274","phase":"NA","title":"The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch","status":"NOT_YET_RECRUITING","sponsor":"Aalborg University","startDate":"2025-12-01","conditions":"Itchiness","enrollment":30},{"nctId":"NCT05860881","phase":"PHASE3","title":"Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2024-02-09","conditions":"Solid Organ Transplant Recipients, Skin Cancer","enrollment":146},{"nctId":"NCT05765487","phase":"PHASE1","title":"Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%","status":"COMPLETED","sponsor":"Daré Bioscience, Inc.","startDate":"2023-05-13","conditions":"Sexual Arousal Disorder","enrollment":13},{"nctId":"NCT06631170","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":"Atopic Dermatitis (AD)","enrollment":354},{"nctId":"NCT06880276","phase":"PHASE3","title":"Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-05-16","conditions":"Atopic Dermatitis","enrollment":360},{"nctId":"NCT04896385","phase":"PHASE2","title":"A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-06-23","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT06531512","phase":"PHASE2, PHASE3","title":"Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2024-08-16","conditions":"Diabetic Foot Ulcer","enrollment":120},{"nctId":"NCT04313400","phase":"PHASE1, PHASE2","title":"Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Amytrx Therapeutics, Inc.","startDate":"2020-03-10","conditions":"Atopic Dermatitis","enrollment":91},{"nctId":"NCT04921969","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-07-19","conditions":"Atopic Dermatitis","enrollment":330},{"nctId":"NCT04962139","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2021-07-27","conditions":"Chronic Diabetic Foot Ulcers","enrollment":12},{"nctId":"NCT06058000","phase":"PHASE2","title":"A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-11-13","conditions":"Atopic Dermatitis","enrollment":120},{"nctId":"NCT05332366","phase":"PHASE2","title":"A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2022-04-19","conditions":"Frontal Fibrosing Alopecia","enrollment":35},{"nctId":"NCT01722812","phase":"PHASE2","title":"Cromoglicate in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-11","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02103725","phase":"PHASE1","title":"A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT01850849","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-05","conditions":"Atopic Dermatitis","enrollment":23},{"nctId":"NCT02427724","phase":"EARLY_PHASE1","title":"The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2015-04","conditions":"Lentigo","enrollment":48},{"nctId":"NCT04685577","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-07-10","conditions":"Burn; Multiple Body Regions, Max. Second Degree, Third-Degree Burn, Burn Degree Second","enrollment":60},{"nctId":"NCT06733402","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-06-20","conditions":"Acne Vulgaris","enrollment":1000},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT03680131","phase":"PHASE2","title":"Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis","status":"COMPLETED","sponsor":"Edesa Biotech Inc.","startDate":"2019-10-15","conditions":"Allergic Contact Dermatitis","enrollment":211},{"nctId":"NCT06673654","phase":"PHASE1","title":"A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-08-11","conditions":"Atopic Dermatitis","enrollment":476},{"nctId":"NCT05550337","phase":"PHASE3","title":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2022-09-19","conditions":"Acne Vulgaris","enrollment":807},{"nctId":"NCT05763082","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2023-02-07","conditions":"Plaque Psoriasis","enrollment":414},{"nctId":"NCT04811131","phase":"PHASE2","title":"Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo","status":"TERMINATED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-03-04","conditions":"Vitiligo","enrollment":114},{"nctId":"NCT03332303","phase":"PHASE3","title":"Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy","status":"COMPLETED","sponsor":"Prasco LLC","startDate":"2017-10-26","conditions":"Vulvar and Vaginal Atrophy","enrollment":540},{"nctId":"NCT04378569","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-04-20","conditions":"Chronic Hand Eczema","enrollment":230},{"nctId":"NCT04435392","phase":"PHASE1, PHASE2","title":"Jaktinib Hydrochloride Cream For Atopic Dermatitis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-10-14","conditions":"Atopic Dermatitis","enrollment":107},{"nctId":"NCT05387707","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2022-08-16","conditions":"Pruritus, Atopic Dermatitis","enrollment":287},{"nctId":"NCT04037475","phase":"NA","title":"Treatment of Herpes Labialis by Photodynamic Therapy","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2020-01-01","conditions":"Photodynamic Therapy, Herpes Simplex, Labial","enrollment":24},{"nctId":"NCT04020419","phase":"EARLY_PHASE1","title":"Natural Berry Extract Treatment of Hemangiomas","status":"TERMINATED","sponsor":"Gayle Gordillo","startDate":"2020-12-01","conditions":"Hemangioma","enrollment":12},{"nctId":"NCT06063473","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-02-22","conditions":"Acne Vulgaris","enrollment":762},{"nctId":"NCT04307862","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis","status":"UNKNOWN","sponsor":"Shulov Innovate for Science Ltd. 2012","startDate":"2019-12-29","conditions":"Atopic Dermatitis","enrollment":165},{"nctId":"NCT01039584","phase":"NA","title":"A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2008-02","conditions":"Vulvovaginal Candidiasis","enrollment":611},{"nctId":"NCT00185510","phase":"PHASE4","title":"Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-03","conditions":"Dermatitis, Atopic","enrollment":250},{"nctId":"NCT05078827","phase":"PHASE3","title":"Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Encube Ethicals Pvt. Ltd.","startDate":"2022-03-01","conditions":"Actinic Keratoses","enrollment":458},{"nctId":"NCT02402309","phase":"PHASE2","title":"A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2015-03","conditions":"Sjögren-Larsson Syndrome","enrollment":12},{"nctId":"NCT04211389","phase":"PHASE3","title":"Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-17","conditions":"Chronic Plaque Psoriasis","enrollment":442},{"nctId":"NCT02925793","phase":"PHASE2","title":"Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)","status":"COMPLETED","sponsor":"DS Biopharma","startDate":"2016-12","conditions":"Atopic Dermatitis","enrollment":327},{"nctId":"NCT02688270","phase":"PHASE2","title":"Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon","status":"COMPLETED","sponsor":"Covis Pharma S.à.r.l.","startDate":"2016-06","conditions":"Raynaud's Phenomenon Secondary to Connective Tissue Disease","enrollment":65},{"nctId":"NCT03850483","phase":"PHASE2","title":"Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-04-08","conditions":"Psoriasis","enrollment":344},{"nctId":"NCT04451330","phase":"PHASE4","title":"A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-07-29","conditions":"Acne Vulgaris","enrollment":202},{"nctId":"NCT00778700","phase":"PHASE2","title":"A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2008-10-28","conditions":"Psoriasis","enrollment":199},{"nctId":"NCT00820950","phase":"PHASE2","title":"A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2007-05-31","conditions":"Psoriasis","enrollment":29},{"nctId":"NCT04882631","phase":"PHASE1","title":"A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants","status":"COMPLETED","sponsor":"Pyramid Biosciences","startDate":"2021-04-12","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT05148689","phase":"PHASE1","title":"A Study Comparing Oxymetazoline 1% Cream to RHOFADE","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2018-02-23","conditions":"Bioequivalence","enrollment":82},{"nctId":"NCT00802672","phase":"PHASE3","title":"Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2003-12","conditions":"Tinea Pedis","enrollment":561},{"nctId":"NCT03540043","phase":"PHASE2","title":"Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"PurGenesis Technologies Inc.","startDate":"2017-10-23","conditions":"Atopic Dermatitis Eczema","enrollment":162},{"nctId":"NCT03846648","phase":"PHASE1","title":"CyPep-1 in Cutaneous Warts","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2019-03-11","conditions":"Cutaneous Warts","enrollment":56},{"nctId":"NCT03954444","phase":"PHASE3","title":"A Clinical Endpoint Bioequivalence Study of \"Oxymetazoline Hydrochloride Cream\"","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-04-15","conditions":"Rosacea","enrollment":1105},{"nctId":"NCT00847912","phase":"PHASE4","title":"CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2009-06-26","conditions":"Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms","enrollment":954},{"nctId":"NCT01268527","phase":"PHASE2","title":"A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2010-03-15","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT02601105","phase":"NA","title":"Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2014-10","conditions":"Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks","enrollment":15},{"nctId":"NCT03903822","phase":"PHASE2","title":"Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-05-13","conditions":"Atopic Dermatitis","enrollment":292},{"nctId":"NCT02616250","phase":"PHASE4","title":"MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-12","conditions":"Rosacea","enrollment":190},{"nctId":"NCT03096457","phase":"PHASE2, PHASE3","title":"Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia","status":"COMPLETED","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2017-04-15","conditions":"Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex, Leishmaniasis, American","enrollment":80},{"nctId":"NCT03386032","phase":"PHASE3","title":"8-Week Atopic Dermatitis (AD) Treatment Study","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2017-11-27","conditions":"Atopic Dermatitis Eczema","enrollment":65},{"nctId":"NCT02165605","phase":"NA","title":"HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-08","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT04586816","phase":"NA","title":"Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging","status":"COMPLETED","sponsor":"Integrative Skin Science and Research","startDate":"2019-09-10","conditions":"Photoaging, Hyperpigmentation, Rhytides","enrollment":19},{"nctId":"NCT00563433","phase":"PHASE3","title":"MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers","status":"COMPLETED","sponsor":"Abeona Therapeutics, Inc","startDate":"1994-08","conditions":"Diabetic Foot Ulcers","enrollment":342},{"nctId":"NCT00563394","phase":"PHASE3","title":"MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers","status":"COMPLETED","sponsor":"Abeona Therapeutics, Inc","startDate":"1994-08","conditions":"Diabetic Foot Ulcers","enrollment":584},{"nctId":"NCT04203342","phase":"PHASE3","title":"A Therapeutic Equivalence Study of Ketoconazole Cream 2%","status":"COMPLETED","sponsor":"Douglas Pharmaceuticals America Ltd","startDate":"2019-12-11","conditions":"Tinea Pedis","enrollment":682},{"nctId":"NCT02840461","phase":"PHASE3","title":"Clinical Endpoint Study of Ivermectin 1% Cream","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-06","conditions":"Moderate to Severe Papulopustular Rosacea","enrollment":630},{"nctId":"NCT02210689","phase":"PHASE3","title":"A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2014-01","conditions":"BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency","enrollment":604},{"nctId":"NCT02014376","phase":"PHASE2","title":"Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Scioderm, Inc.","startDate":"2014-01-06","conditions":"Epidermolysis Bullosa","enrollment":48},{"nctId":"NCT03294538","phase":"PHASE3","title":"Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-05-18","conditions":"Atrophic Vaginitis","enrollment":663},{"nctId":"NCT02556788","phase":"PHASE3","title":"Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-11","conditions":"Acne Vulgaris","enrollment":1212},{"nctId":"NCT02566369","phase":"PHASE3","title":"Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-11-30","conditions":"Acne Vulgaris","enrollment":1208},{"nctId":"NCT02095990","phase":"PHASE3","title":"Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma","status":"COMPLETED","sponsor":"Mesoestetic Pharma Group S.L.","startDate":"2014-03","conditions":"Facial Melasma","enrollment":17},{"nctId":"NCT02616601","phase":"PHASE3","title":"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02-27","conditions":"Actinic Keratosis","enrollment":422},{"nctId":"NCT03824912","phase":"PHASE3","title":"Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis","status":"COMPLETED","sponsor":"Encube Ethicals Pvt. Ltd.","startDate":"2018-08-23","conditions":"Tinea Pedis","enrollment":831},{"nctId":"NCT02871479","phase":"PHASE2","title":"A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Santalis Pharmaceuticals, Inc.","startDate":"2017-04-21","conditions":"Atopic Dermatitis, Eczema","enrollment":71},{"nctId":"NCT03307577","phase":"PHASE2","title":"A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2017-10-05","conditions":"Acne Vulgaris","enrollment":52},{"nctId":"NCT03688971","phase":"PHASE2","title":"Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis","status":"UNKNOWN","sponsor":"Maruho Co., Ltd.","startDate":"2018-10-22","conditions":"Seborrheic Dermatitis","enrollment":36},{"nctId":"NCT03210740","phase":"PHASE2","title":"Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"AmDerma","startDate":"2017-06-06","conditions":"Actinic Keratosis","enrollment":30},{"nctId":"NCT03116698","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-02-14","conditions":"Actinic Keratosis (AK)","enrollment":240},{"nctId":"NCT01235728","phase":"PHASE1","title":"A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-01","conditions":"Psoriasis, Plaque Psoriasis","enrollment":24},{"nctId":"NCT03000595","phase":"PHASE2","title":"A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis","status":"WITHDRAWN","sponsor":"Santalis Pharmaceuticals, Inc.","startDate":"2018-06","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT02965118","phase":"PHASE3","title":"CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2016-11","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT02748993","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2016-03","conditions":"Atopic Dermatitis","enrollment":56},{"nctId":"NCT03089229","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis","status":"COMPLETED","sponsor":"Haus Bioceuticals","startDate":"2017-03-26","conditions":"Atopic Dermatitis, Eczema","enrollment":30},{"nctId":"NCT02484170","phase":"PHASE1, PHASE2","title":"Mannitol Cream for Post Herpetic Neuralgia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-09-30","conditions":"Neuralgia, Postherpetic","enrollment":20},{"nctId":"NCT03005964","phase":"PHASE2","title":"Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"AmDerma","startDate":"2016-12","conditions":"Plaque Psoriasis","enrollment":74},{"nctId":"NCT03431610","phase":"PHASE1","title":"A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2017-11-13","conditions":"Atopic Dermatitis","enrollment":48},{"nctId":"NCT02886702","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-19","conditions":"Plaque Psoriasis","enrollment":855},{"nctId":"NCT02886715","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-21","conditions":"Acne Vulgaris","enrollment":1110},{"nctId":"NCT03142178","phase":"PHASE1, PHASE2","title":"3VM for Treatment of Chronic Osteoarthritis Knee Pain","status":"COMPLETED","sponsor":"CDA Research Group, Inc.","startDate":"2017-04-30","conditions":"Arthritis, Degenerative","enrollment":150},{"nctId":"NCT03433378","phase":"EARLY_PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2017-08-04","conditions":"Acne Vulgaris","enrollment":700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo/Vehicle cream","genericName":"Placebo/Vehicle cream","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}